A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
NCT02135692
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
339
Enrollment
INDUSTRY
Sponsor class
Conditions
Asthma
Interventions
BIOLOGICAL:
Mepolizumab
DRUG:
SOC
Sponsor
GlaxoSmithKline